![]() The preferred perioperative treatment approach for patients with esophageal squamous cell carcinoma (ESCC), esophageal adenocarcinoma, or Siewert I/II GEJ adenocarcinoma is trimodality therapy with chemoradiation followed by surgery. Neoadjuvant Chemoradiation in Esophageal and GEJ Cancer Preoperative Treatment Approaches for Esophageal and GEJ Cancer This review aims to clarify the current state of clinical practice and clinical research pertaining to the preoperative and postoperative treatment of patients with a diagnosis of cT2 or higher esophageal, GEJ, or gastric cancer. For some clinical T2 (cT2) and nearly all cT3/cT4 and/or node-positive esophageal, GEJ, and gastric cancers, a multimodality approach is now the standard of care. 1,2 For selected cases of early-stage esophageal, gastroesophageal junction (GEJ), or gastric cancer, surgery is the primary treatment. Gastric cancer and esophageal cancer are the third- and sixth-leading causes of cancer death worldwide, respectively. More than 45,000 new cases of esophageal and gastric cancer are diagnosed in the United States each year, and these result in more than 27,000 deaths annually. This review highlights the current standard-of-care approaches and areas of ongoing clinical research, including biomarker-directed therapy, pertaining to the treatment of esophageal, gastroesophageal junction, and gastric cancers in patients who are candidates for therapy with curative intent. The optimal content and sequence of perioperative treatment of patients with different sites of disease and tumor histologic types continue to evolve. Abstract: Multimodality therapy, which can include systemic therapy, radiation therapy, and surgery, is the preferred approach for most localized, clinical T2 to T4, and/or node-positive esophageal, gastroesophageal junction, and gastric cancers. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |